Search - tctmd.com

Displaying 841 - 860 of 1067

Sort: Relevancy | Date

Presentation

PCI with DES vs CABG in Women with Severe Narrowing of the Left Main Coronary Artery

Presenter: G.L. Buchanan

February 23, 2014

News Daily News

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

February 12, 2014

News Daily News

DUTCH PEERS Publicado: Los Stents liberadores de Zotarolimus y Everolimus de 3ª Generación son Equivalentes

February 12, 2014

Presentation

Third-Gen ZES and EES in All-Comers Patients Requiring PCI: DUTCH PEERS Noninferiority Trial

Presenter: Clemens von Birgelen

February 09, 2014

News Daily News

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

January 09, 2014

News Daily News

Comparados con los SMD, los SLE Reducen la Revascularización con Independencia de la Severidad de la Enfermedad Renal

January 09, 2014

News Daily News

Un Análisis Revela que, comparados con los SMD, los SLF Reducen la RVD pero No la Mortalidad en Pacientes Muy Ancianos

December 30, 2013

News Daily News

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

December 30, 2013

Presentation

ST with Second-generation DES vs. BMS: Network Meta-analysis of Primary PCI Trials in STEMI

Presenter: 183206|Femi Philip

December 08, 2013

Presentation TCT 2013

Treatment of Complex Multivessel PCI. A New Sirolimus Chromium Cobalt Alloy DES. Study Design and Case Presentation

Presenter: Carlos Fernandez-Pereira

October 30, 2013

Presentation TCT 2013

Navigating the Stent Era (from Bare Metal to Drug-Eluting): The Transformation of PCI

Presenter: Patrick Serruys

October 30, 2013

Presentation TCT 2013

Yes! With Current DES and Pharmacotherapy, SYNTAX Is Already Obsolete and the Majority of Patients with MVD Can Be Managed with PCI

Presenter: Dean Kereiakes

October 28, 2013

Presentation TCT 2013

Quantifying the Quality-of-Life Benefits of PCI in Stable Ischemic Heart Disease

Presenter: John Spertus

October 28, 2013

Presentation TCT 2013

Importance of Incomplete Revascularization after PCI: Anticipating RIVER-PCI

Presenter: Giora Weisz

October 28, 2013

Presentation TCT 2013

Treatment Considerations in Patients with Valvular Heart Disease Requiring PCI: Stent Selection, Pharmacotherapy, and Timing

Presenter: James Hermiller Jr

October 28, 2013

Presentation TCT 2013

Should the Presence of Diabetes Move Treatment Toward CABG Rather Than PCI? Historical Observations and Syntax Score II

Presenter: Patrick Serruys

October 28, 2013

Presentation TCT 2013

Implications of Periprocedural CKMB and Troponin Elevations After PCI: A Critical Appraisal

Presenter: Donald Cutlip

October 28, 2013

Presentation TCT 2013

Does PCI Reduce Mortality in Stable Patients with Ischemia? Results of a New Meta-analysis

Presenter: Ajay Kirtane

October 28, 2013

Presentation TCT 2013

Does Cilostazol Have a Role in Contemporary PCI?

Presenter: Frederick Feit

October 28, 2013

Presentation TCT 2013

Vascular Responses after PCI: Theoretical Differences between a Permanently Caged and Liberated Vessel

Presenter: Patrick Serruys

October 27, 2013

Advertisement

PCI with DES vs CABG in Women with Severe Narrowing of the Left Main Coronary Artery

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

DUTCH PEERS Publicado: Los Stents liberadores de Zotarolimus y Everolimus de 3ª Generación son Equivalentes

Third-Gen ZES and EES in All-Comers Patients Requiring PCI: DUTCH PEERS Noninferiority Trial

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

Comparados con los SMD, los SLE Reducen la Revascularización con Independencia de la Severidad de la Enfermedad Renal

Un Análisis Revela que, comparados con los SMD, los SLF Reducen la RVD pero No la Mortalidad en Pacientes Muy Ancianos

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

ST with Second-generation DES vs. BMS: Network Meta-analysis of Primary PCI Trials in STEMI

Treatment of Complex Multivessel PCI. A New Sirolimus Chromium Cobalt Alloy DES. Study Design and Case Presentation

Navigating the Stent Era (from Bare Metal to Drug-Eluting): The Transformation of PCI

Yes! With Current DES and Pharmacotherapy, SYNTAX Is Already Obsolete and the Majority of Patients with MVD Can Be Managed with PCI

Quantifying the Quality-of-Life Benefits of PCI in Stable Ischemic Heart Disease

Importance of Incomplete Revascularization after PCI: Anticipating RIVER-PCI

Treatment Considerations in Patients with Valvular Heart Disease Requiring PCI: Stent Selection, Pharmacotherapy, and Timing

Should the Presence of Diabetes Move Treatment Toward CABG Rather Than PCI? Historical Observations and Syntax Score II

Implications of Periprocedural CKMB and Troponin Elevations After PCI: A Critical Appraisal

Does PCI Reduce Mortality in Stable Patients with Ischemia? Results of a New Meta-analysis

Does Cilostazol Have a Role in Contemporary PCI?

Vascular Responses after PCI: Theoretical Differences between a Permanently Caged and Liberated Vessel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content